| 紫杉醇脂质体联合奈达铂治疗晚期非小细胞肺癌的临床研究 |
| |
| 引用本文： | 罗海清,官成浓,陈梓宏,杨东红,余忠华.紫杉醇脂质体联合奈达铂治疗晚期非小细胞肺癌的临床研究[J].肿瘤研究与临床,2013(12):803-805. |
| |
| 作者姓名： | 罗海清 官成浓 陈梓宏 杨东红 余忠华 |
| |
| 作者单位： | 广东医学院附属医院肿瘤中心二区,湛江524001 |
| |
| 摘 要： | 目的 观察紫杉醇脂质体联合奈达铂一线治疗晚期非小细胞肺癌（NSCLC）的临床效果、生存期和患者不良反应.方法 34例晚期NSCLC患者,静脉注射紫杉醇脂质体150 mg/m2,第1天,奈达铂80 mg/ m2,第1天,21d为1个周期.所有患者接受至少2个周期以上化疗,平均每2个周期评估临床疗效、相关不良反应.结果 34例患者均可评价临床疗效和不良反应,患者共接受174个周期化疗,中位化疗周期为5.3个周期,紫杉醇脂质体联合奈达铂的客观反应率为32.3％,疾病控制率为67.6％,中位总生存期为9.5个月（95％CI6.2 ～ 10.7）,1年生存率为40.6％.该方案主要的不良反应是血液学和非血液学毒性,其中Ⅲ～Ⅳ度中性粒细胞减少症发生率为41.7％,Ⅲ～Ⅳ度贫血发生率为17.6％,Ⅲ～Ⅳ度血小板减少症发生率为8.8％,Ⅲ～Ⅳ度呕吐发生率为8.8％,Ⅲ～Ⅳ度腹泻发生率为5.8％.结论 紫杉醇脂质体联合奈达铂方案一线治疗晚期NSCLC的临床疗效好,且不良反应较小,患者耐受性好,可作为晚期NSCLC一线化疗的一种新方案.
|
| 关 键 词： | 脂质体 紫杉醇 奈达铂 癌 非小细胞肺 药物疗法 联合 |
Clinical research of liposome paclitaxel combined with nedaplatin in treatment of advanced non-small cell lung cancer |
| |
| LUO Hai-qing;GUAN Cheng-nong;CHEN Zi-hong;YANG Dong-hong;YU Zhong-hua.Clinical research of liposome paclitaxel combined with nedaplatin in treatment of advanced non-small cell lung cancer[J].Cancer Research and Clinic,2013(12):803-805. |
| |
| Authors: | LUO Hai-qing;GUAN Cheng-nong;CHEN Zi-hong;YANG Dong-hong;YU Zhong-hua |
| |
| Affiliation: | LUO Hai-qing;GUAN Cheng-nong;CHEN Zi-hong;YANG Dong-hong;YU Zhong-hua(Center of Oncology, the Affiliated Hospital of Guangdong Medical College, Zhanjiang 524001, China) |
| |
| Abstract: | Objective To evaluate the clinical efficacy,overall survival and toxicities in the patients with advanced non-small cell lung cancer treated by liposome paclitaxel combined with nedaplatin as first-line treating.Methods 34 cases with advanced NSCLC were treated with liposome paclitaxel 150 mg/m2 on day 1 and nedaplatin 80 mg/m2 on day 1 by intravenous infusion,with 21 days as one cycle.The patients were treated with chemotherapy more than 2 cycles.Efficacy evaluation and adverse events were evaluated every 2 cycles.Results 34 patients were available for evaluation of efficacy and adverse events.The patients recieved 174 cycles of chemotherapy,and the median was 5.3 cycles.The objective response rate of liposome paclitaxel combined with nedaplatin was 32.3 ％,the disease control rate was 67.6 ％,the median overall survival was 9.5 months （95 ％ CI 6.2-10.7）,1 years survival rate was 40.6 ％.The main adverse events were hematological and gastrointestinal toxicities.Frequent grade Ⅲ-Ⅳ toxicities included neutropenia （41.7 ％）,anemia （17.6 ％）,thrombocytopenia （8.8 ％）,nausea and vomiting （8.8 ％）,diarrhea （5.8 ％）.Conclusions The regimen of liposome paclitaxel combined with nedaplatin is against advanced non-small cell lung cancer with high efficacy and acceptable toxicities,and it may be used as a new choice for treatment of advanced non-small cell lung cancer. |
| |
| Keywords: | Liposome Paclitaxel Nedaplatin Carcinoma non-small-cell lung Drug therapy combination |
| 本文献已被 维普 等数据库收录！ |
|
